CN101528244B - 用于降低疾病发生率和病期的益生菌剂 - Google Patents

用于降低疾病发生率和病期的益生菌剂 Download PDF

Info

Publication number
CN101528244B
CN101528244B CN2007800366675A CN200780036667A CN101528244B CN 101528244 B CN101528244 B CN 101528244B CN 2007800366675 A CN2007800366675 A CN 2007800366675A CN 200780036667 A CN200780036667 A CN 200780036667A CN 101528244 B CN101528244 B CN 101528244B
Authority
CN
China
Prior art keywords
children
disease
symptoms
group
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800366675A
Other languages
English (en)
Chinese (zh)
Other versions
CN101528244A (zh
Inventor
G·莱尔
A·乌维汉德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Danisco Sweeteners Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101528244(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Danisco Sweeteners Oy filed Critical Danisco Sweeteners Oy
Publication of CN101528244A publication Critical patent/CN101528244A/zh
Application granted granted Critical
Publication of CN101528244B publication Critical patent/CN101528244B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2007800366675A 2006-10-02 2007-09-14 用于降低疾病发生率和病期的益生菌剂 Active CN101528244B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84866206P 2006-10-02 2006-10-02
US60/848,662 2006-10-02
PCT/US2007/020033 WO2008042101A2 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing the incidence and duration of illness

Publications (2)

Publication Number Publication Date
CN101528244A CN101528244A (zh) 2009-09-09
CN101528244B true CN101528244B (zh) 2012-01-11

Family

ID=39268947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800366675A Active CN101528244B (zh) 2006-10-02 2007-09-14 用于降低疾病发生率和病期的益生菌剂

Country Status (13)

Country Link
US (5) US20100040579A1 (enExample)
EP (2) EP2839836B2 (enExample)
JP (3) JP5896589B2 (enExample)
KR (2) KR101474188B1 (enExample)
CN (1) CN101528244B (enExample)
AU (1) AU2007302715B2 (enExample)
BR (1) BRPI0719787A2 (enExample)
DK (2) DK2839836T4 (enExample)
ES (2) ES2547480T3 (enExample)
FI (1) FI2839836T4 (enExample)
MX (1) MX2009003260A (enExample)
PL (2) PL2839836T5 (enExample)
WO (1) WO2008042101A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509151B1 (en) 2009-12-02 2014-08-20 KMW Inc. Device selection structure
JP5885287B2 (ja) * 2010-09-02 2016-03-15 アサヒカルピスウェルネス株式会社 インフルエンザの予防および／または治療剤
KR101806435B1 (ko) 2010-10-15 2017-12-07 시에이치알. 한센 에이/에스 면역보강제
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2455093A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
WO2015071389A1 (en) 2013-11-15 2015-05-21 Nestec S.A. Compositions for use in the prevention or treatment of urt infections in infants or young children at risk
CN103798392B (zh) * 2014-03-07 2015-12-30 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
AU2016227595B2 (en) 2015-03-05 2020-08-27 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
WO2020170982A1 (ja) 2019-02-21 2020-08-27 オリンパス株式会社 フローラ治療用留置体、フローラ治療法
WO2021062250A1 (en) 2019-09-25 2021-04-01 Tall Goods, Llc Methods for producing probiotics fortified avian eggs and egg products and formulations thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054135A1 (en) * 2004-11-16 2006-05-26 Anidral S.R.L. Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007A (en) * 1845-04-22 Improvement in separating tannin and coloring-matter in quercitron-bark
AU5113798A (en) * 1996-11-29 1998-06-22 Bio K & International Inc. Lactic ferment comprising a particular strain of (lactobacillus acidophilus) and use thereof
JP4212838B2 (ja) * 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
MXPA05003597A (es) 2002-10-11 2005-06-03 Wyeth Corp Formulaciones nutricionales que contienen sustancias simbioticas.
RU2407784C2 (ru) * 2003-12-17 2010-12-27 Н.В. Нютрисиа Пробиотический штамм lactobacillus casei, продуцирующий молочную кислоту, применение штамма для приготовления питательной композиции для лечения или профилактики легочной дисфункции, питательная композиция и способ ее получения, лекарственное средство для лечения или профилактики хронической обструктивной болезни легких у субъекта и применение штамма для приготовления лекарственного средства, контейнер
DE102004026706A1 (de) * 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7981412B2 (en) * 2005-02-15 2011-07-19 Gorbach Sherwood L Food containing a probiotic and an isolated β-glucan and methods of use thereof
US20070020249A1 (en) * 2005-04-29 2007-01-25 Downs Bernard W Compositions for prevention and treatement of symptoms of gastrointestinal distress
EP1951273B1 (en) 2005-10-06 2014-02-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054135A1 (en) * 2004-11-16 2006-05-26 Anidral S.R.L. Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality

Also Published As

Publication number Publication date
US20140356329A1 (en) 2014-12-04
EP2839836B1 (en) 2017-08-30
ES2547480T3 (es) 2015-10-06
EP2839836B2 (en) 2024-06-26
MX2009003260A (es) 2009-05-11
CN101528244A (zh) 2009-09-09
KR20140002069A (ko) 2014-01-07
ES2650375T3 (es) 2018-01-18
US20200316145A1 (en) 2020-10-08
JP5896589B2 (ja) 2016-03-30
BRPI0719787A2 (pt) 2014-11-25
US20180000875A1 (en) 2018-01-04
JP2014058558A (ja) 2014-04-03
KR20090063222A (ko) 2009-06-17
PL2839836T5 (pl) 2025-11-17
PL2068899T3 (pl) 2015-12-31
KR101474188B1 (ko) 2014-12-17
EP2068899A2 (en) 2009-06-17
DK2839836T3 (en) 2017-12-04
KR101485200B1 (ko) 2015-01-26
EP2839836A1 (en) 2015-02-25
US20100040579A1 (en) 2010-02-18
JP2016128478A (ja) 2016-07-14
WO2008042101A2 (en) 2008-04-10
AU2007302715A1 (en) 2008-04-10
JP2010505824A (ja) 2010-02-25
WO2008042101A3 (en) 2009-04-09
EP2068899B1 (en) 2015-07-01
AU2007302715B2 (en) 2013-01-31
FI2839836T4 (fi) 2024-08-26
DK2839836T4 (da) 2024-08-26
PL2839836T3 (pl) 2018-02-28
US20230256037A1 (en) 2023-08-17
DK2068899T3 (da) 2015-09-28
ES2650375T5 (en) 2025-02-03

Similar Documents

Publication Publication Date Title
US20230256037A1 (en) Probiotics for use in reducing the incidence and duration of illness
Lenoir-Wijnkoop et al. Probiotic and prebiotic influence beyond the intestinal tract
Saavedra et al. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety
Hojsak et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial
TWI374745B (en) Use of a combination of bifidobacterium lactis bb-12 and lactobacillus rhamnosus gg for preventing or treating respiratory infections and acute otitis media in infants
Berggren et al. Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections
Fujita et al. Decreased duration of acute upper respiratory tract infections with daily intake of fermented milk: a multicenter, double-blinded, randomized comparative study in users of day care facilities for the elderly population
EP2209527B1 (en) Pharmaceutical compositions comprising L. acidophilus and Bifidobacterium lactis for use in the treatment of functional bowel disorder
CN101076346B (zh) 乳酸菌及其在预防腹泻中的应用
Banerjee et al. Importance of probiotics in human health
AU2013201783B2 (en) Probiotics for use in reducing the incidence and duration of illness
EP2139502B1 (en) Lactobacillus and bifidobacterium against birch allergy
Wu et al. Bifidobacteria and Lactobacillus rhamnosus affecting respiratory infections and immune function in children
US20190091270A1 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
Varshney An analysis of probiotics
CN119258102A (zh) 后生元组合物及其制备方法和应用
Saljoughian Probiotics: a closer look
Desland et al. Commonly Asked Questions about Probiotics and the Potential Benefits for Your Health: MB005/MB005, 12/2011

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: DUPONT NUTRITION BIOSCIENCES APS

Free format text: FORMER NAME: DANISCO US INC. GENENCOR DIVISI

CP01 Change in the name or title of a patent holder

Address after: Copenhagen

Patentee after: Danisco

Address before: Copenhagen

Patentee before: Danisco US Inc. Genencor Divisi